Gitnux/Report 2026

Compounded Glp-1 Industry Statistics

The global compounded GLP-1 market reached $5.1 billion in 2023—explore the U.S. telehealth value, provider participation, and the 2026 pricing and regulation shifts shaping compounded GLP-1 choices.
23Statistics
22Sources
4Sections
1Visuals
15mRead
How this report is researched
01Editorial Scope

Before any source is gathered, an editor locks the question, what qualifies, and how the piece will be judged.

02Source Research

Search agents collect the source set and pull each data point out with its provenance attached.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The compounded glp-1 industry at a glance

Compounded GLP-1s remain a substantial U.S. access channel: 22.6% of adults who used a GLP-1 medication in 2025 reported taking a compounded version, despite tightening FDA oversight.

22.6%[9]
GLP-1 users taking compounded versions, 2025
9.8%[9]
Adults using GLP-1s, 2025
$299[6]
Median compounded tirzepatide price, 2026
91.8%[10]
Online sellers issuing prescriptions, 2026
Segmentation
The market is primarily segmented by active ingredient and delivery channel: compounded semaglutide and tirzepatide are supplied through compounding pharmacies, telehealth platforms, and direct pharmacy programs. In a 2025 nationwide primary-care dataset, 8.2% of 153,044 patients used compounded GLP-1 formulations, although the study noted that this was not a population-wide market share.[11]
Key players & concentration
The industry is fragmented across telehealth sellers and partner pharmacies rather than dominated by a publicly reported national leader. A 2026 secret-shopper study assessed 49 online GLP-1 websites; 45 issued a prescription and 34 mailed medication, indicating broad participation by digital providers.[10][12]
Pricing
Compounded GLP-1 prices vary by ingredient, dose, provider, membership structure, and shipping. FormBlends reported a median all-in monthly price of $299 for compounded tirzepatide at the 5-mg weekly titration step on September 3, 2026, with the middle half of providers priced at $268–$369.[6]
Trends, drivers & challenges
Demand has been driven by widespread GLP-1 use, affordability concerns, and access to branded products: 38% of GLP-1 users who modified treatment cited cost and 36% cited availability. The main challenges are dosing errors, variable clinical oversight, quality concerns, and the loss of shortage-based compounding eligibility as branded supply improves.[9][8]
Consumer behavior & competition
Compounded products compete mainly on cash price and online convenience, while consumers also face uncertainty about whether a product is compounded: 8.8% of GLP-1 users in the CDC survey did not know their medication’s status. Among compounded users, 62% reported modifying how they used the medication, compared with 36% of users taking noncompounded products.[9]
Regulation
FDA states that compounded GLP-1 products are not reviewed for safety, effectiveness, or quality before marketing. The agency determined that semaglutide injection shortages were resolved on February 21, 2025, and proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-drug list, potentially narrowing outsourcing-facility compounding.[8]
Latest news
In 2026, FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-substances list after finding no clinical need for outsourcing facilities to compound them from bulk ingredients. Separately, a 2026 JAMA study found that 91.8% of 49 online GLP-1 sellers issued a prescription to a simulated eligible patient and 69.4% mailed medication.[8][10]

02 Ranking

Top 10 Companies in the Compounded Glp-1 Industry

The leading companies in the compounded glp-1 industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Empower Pharmacy leads the compounded glp-1 industry with semaglutide and tirzepatide compounded through 503A and 503B facilities, while Strive Pharmacy stands out with compounded semaglutide and tirzepatide injections listed among its popular products.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in compounded GLP-1 dispensing

    Empower Pharmacy

    US

    Ranked #1 · 9.6 · Compounded GLP-1 dispensing

    Why we picked it: It compounds semaglutide and tirzepatide using both 503A and 503B facilities in a nationwide model.

  2. #2 overall

    Strive Pharmacy

    US

    Ranked #2 · 9.3 · Compounded GLP-1 dispensing

    Why we picked it: It lists compounded semaglutide and tirzepatide injections as part of its popular product set.

  3. #3 overall

    OrderlyMeds

    US

    Ranked #3 · 9.2 · Compounded GLP-1 dispensing

    Why we picked it: It reports 125,000 customers and offers compounded semaglutide and tirzepatide.

Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.

Full ranking

Sort by
Top 10 companies in the compounded glp-1 industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Empower Pharmacy

Compounded GLP-1 dispensing · US

9.6
2

Strive Pharmacy

Compounded GLP-1 dispensing · US

9.3
3

OrderlyMeds

Compounded GLP-1 dispensing · US

9.2
4

Mochi Health

Compounded GLP-1 dispensing · US

9.1
5

Hallandale Pharmacy

Compounded GLP-1 dispensing · US

9.1
6

Olympia Pharmacy

503A/503B compounded medications, US · US

9.1
7

Belmar Pharma Solutions

Compounded GLP-1s and specialty pharmacy, US · US

8.7
8

Henry Meds

Telehealth compounded GLP-1 care, US · US

8.6
9

Fifty 410

Telehealth GLP-1 fulfillment platform, US · US

8.4
10

Willow

Online compounded GLP-1 care, US · US

7.4

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the compounded glp-1 industry. In Compounded Glp-1 Industry Statistics. Gitnux. https://gitnux.org/compounded-glp-1-industry-statistics/#top-companies

report visual · Comparison

Compounded weight-loss prescriptions by active drug (Nebraska, United States)

semaglutide holds the largest share at 40.1%.

semaglutide40.1%
tirzepatide36.6%
phentermine23.3%
source-verifiedjamanetwork.com

04 Statistics

Market Intelligence

We track compounded GLP-1 demand through both overall and telehealth-defined value. The 2025 U.S. telehealth estimate is $3.11 billion, alongside a $5.80 billion compounded GLP-1 market value.

Market size, volume and shipments in the compounded glp-1 industry

  • $5.1 billion was the estimated global compounded GLP-1 market size in 2023; the publisher defines the category as compounded GLP-1 medicines within the broader compounding-pharmacy market.[1]
  • $3.11 billion was the estimated U.S. compounded GLP-1 telehealth market value in 2025, covering the telehealth-distributed segment rather than all compounded GLP-1 sales.[2]
  • $5.80 billion was the estimated compounded GLP-1 market value in 2025; the publisher does not specify a narrower geography on the cited page.[3]

Forecast growth and shipments in the compounded glp-1 industry

  • 9.0% was the projected compound annual growth rate for the compounded GLP-1 market from 2026 to 2035, based on Strategic Revenue Insights’ market definition.[3]
  • $13.73 billion was the projected compounded GLP-1 market value for 2035 under Strategic Revenue Insights’ market definition.[3]
  • 3.0% was the projected compound annual growth rate for the U.S. compounded GLP-1 telehealth market from 2026 to 2035.[2]
  • $4.18 billion was the projected U.S. compounded GLP-1 telehealth market value for 2035.[2]

05 Statistics

Production & Operations

Conformance varies across suppliers serving weight-loss clinics. The study found 19.0% of 21 identified facilities were not licensed for sterile compounding after shortages ended, and 13.6% of 22 faced state-level disciplinary action since 2023.

Defects and conformance in the compounded glp-1 industry

  • 19.0% of 21 identified compounding facilities supplying U.S. weight-loss clinics were not licensed for sterile compounding; the study assessed compounded GLP-1 suppliers after semaglutide and tirzepatide shortages ended.[4]
  • 13.6% of 22 identified compounded GLP-1 suppliers had faced state-level disciplinary action since 2023, indicating a documented conformance issue among suppliers serving U.S. weight-loss businesses.[4]
  • Compounded GLP-1 products had a 19.00 reporting-odds ratio for contamination versus non-compounded products in FDA FAERS data covering 2018–2024.[5]

06 Statistics

Pricing & Finance

Cash pricing stays tightly tiered by ingredient and titration step. For example, FormBlends reports $299 per month as the median all-in compounded tirzepatide price at the 5-mg weekly titration step on September 3, 2026.

Prices and price indices for compounded glp-1

  • $299 per month was the median all-in price for compounded tirzepatide at 5 mg/week, month 4, across 12 U.S. providers on September 3, 2026.[6]
  • $199 per month was the median all-in price for compounded semaglutide at 1 mg/week, month 4, across 13 U.S. providers on September 3, 2026.[6]
  • $249 per month was the median regular cash price for compounded oral semaglutide across five U.S. telehealth programs, with prices checked November 2–10, 2026.[7]

07 Statistics

Regulation & Risk

FDA oversight and enforcement activity remains prominent. In 2025, FDA issued 72 compounding-related warning letters, and 58 of the 72 addressed misbranded compounded drugs promoted through false or misleading advertising.

Regulations and compliance for compounded glp-1

  • 60 calendar days was FDA’s enforcement-discretion period for U.S. 503A compounders copying semaglutide injection products after the shortage was resolved, ending April 22, 2025, under the FD&C Act.[8]
  • 90 calendar days was FDA’s enforcement-discretion period for U.S. 503B outsourcing facilities copying semaglutide injection products, ending May 22, 2025, under the FD&C Act.[8]
  • 60 calendar days was FDA’s enforcement-discretion period for U.S. 503A compounders copying tirzepatide injections after the shortage was resolved, ending February 18, 2025, under the FD&C Act.[8]

Enforcement and penalties in the compounded glp-1 industry

  • 72 compounding-related warning letters were issued in 2025 by FDA, covering compounded-drug compliance actions in the United States.[8]
  • 6 regulatory meetings with compounders were held by FDA in 2025 as part of U.S. compounding compliance activity.[8]
  • 5 untitled letters were issued to compounding facilities in 2025 by FDA as part of U.S. compounding enforcement activity.[8]
  • 58 of FDA’s 72 compounding-related warning letters in 2025 addressed misbranded compounded drugs promoted through false or misleading advertising, including implied equivalence to approved products.[8]

Recalls and safety notices for compounded glp-1

  • More than 730 adverse-event reports associated with compounded tirzepatide had been received by FDA as of May 31, 2026; federal reporting requirements do not cover many state-licensed pharmacies.[8]
  • 1 adverse event was reported to FDA in connection with a fraudulent product labeled as compounded tirzepatide from a pharmacy that did not actually compound it; symptoms included injection-site redness, swelling, pain and a lump.[8]
  • 990 adverse-event reports associated with compounded semaglutide had been received by FDA as of May 31, 2026; federal reporting requirements do not cover many state-licensed pharmacies.[8]

Key questions about the compounded glp-1 industry

How large is the compounded GLP-1 market in the U.S. and globally?
The estimated global compounded GLP-1 market size was $5.1 billion in 2023. The estimated U.S. compounded GLP-1 telehealth market value was $3.11 billion in 2025, while the estimated compounded GLP-1 market value was $5.80 billion in 2025.
What growth is projected for compounded GLP-1 through 2035?
A projected compound annual growth rate of 9.0% runs from 2026 to 2035 for the compounded GLP-1 market under Strategic Revenue Insights’ definition. That projects a $13.73 billion market value for 2035.
Which companies lead the compounded glp-1 industry?
Empower Pharmacy leads the compounded glp-1 industry with semaglutide and tirzepatide compounded through 503A and 503B facilities, while Strive Pharmacy stands out with compounded semaglutide and tirzepatide injections listed among its popular products.
What technology or delivery shifts show up in the 2025–2026 data?
Online sellers issued prescriptions for 91.8% of simulated purchases in 2026. In the same 2026 JAMA study, 69.4% mailed medication after issuing prescriptions to a simulated eligible patient.
How is the market structured across providers and fulfillment routes?
The market is segmented by active ingredient and delivery channel, with compounded semaglutide and tirzepatide supplied through compounding pharmacies, telehealth platforms, and direct pharmacy programs. A 2026 secret-shopper study assessed 49 online GLP-1 websites, with 45 issuing prescriptions and 34 mailing medication.
What regulatory and safety risks affect compounded GLP-1 operations?
FDA states compounded GLP-1 products are not reviewed for safety, effectiveness, or quality before marketing. More than 730 adverse-event reports for compounded tirzepatide and 990 adverse-event reports for compounded semaglutide were received by FDA as of May 31, 2026.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Compounded Glp-1 Industry Statistics. Gitnux. https://gitnux.org/compounded-glp-1-industry-statistics
MLA
Samuel Norberg. "Compounded Glp-1 Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/compounded-glp-1-industry-statistics.
Chicago
Samuel Norberg. 2026. "Compounded Glp-1 Industry Statistics." Gitnux. https://gitnux.org/compounded-glp-1-industry-statistics.